Market Overview

UPDATE: Piper Jaffray Initiates Threshold Pharmaceuticals at Neutral Ahead of Pivotal Data

Related THLD
US Stock Futures Flat After Record Close
Threshold Pharma Reports New Clinical Data on TH-302, Says One CR, Two Partial

Piper Jaffray initiated coverage on Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) with a Neutral rating and a $5.00 price target.

Piper Jaffray noted, "Lead candidate TH-302 ('302) has a well characterized “warhead” modified with a hypoxia-activated trigger that targets activity to the tumor core, which may be neglected by traditional chemotherapy and a source of recurrence. '302 is in pivotal testing for sarcoma and pancreatic cancer, with data later in 2013 that we believe may be positive, based on our diligence on ‘302's mechanism and prior clinical results. However, we remain on the sidelines pending pivotal data that confirms the "hypoxia-hypothesis" and enhances clarity on the efficacy/safety of the drug that may provide it competitive advantage over drugs from Celgene (pancreatic) and Ziopharm (sarcoma)."

Threshold Pharmaceuticals closed at $4.51 on Thursday.

Posted-In: Piper JaffrayAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Most Popular

Related Articles (THLD)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free